<DOC>
	<DOCNO>NCT02920398</DOCNO>
	<brief_summary>Investigating single dose pharmacokinetics safety turoctocog alfa pegol pivotal process turoctocog alfa pegol commercial process patient severe haemophilia A</brief_summary>
	<brief_title>A Multi-centre , Comparative , Double Blind , Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics Safety Turoctocog Alfa Pegol From Pivotal Process Turoctocog Alfa Pegol From Commercial Process Patients With Severe Haemophilia A .</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Informed consent obtain trialrelated activity . Trialrelated activity procedure carry part trial , include activity determine suitability trial Ongoing participation pathfinder™2 Male , age least 12 year time signing inform consent ( certain country low age limit 18 year , accord local requirement ) FVIII inhibitor ( ≥0.6 BU ) last visit pathfinder™2 prior entry pathfinder™7 Planned surgery trial Major surgery perform within 4 week prior screen Previous participation trial . Participation define sign informed consent Any disorder , except condition associate haemophilia A , investigator 's opinion might jeopardise patient 's safety compliance protocol</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>